Radar · Cell Therapy in United States
Best Cell Therapy Companies in United States
The 328 best Cell Therapy companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sana Biotechnology.
By Riya SenguptaFinancials
328companies tracked
$16.9Bdisclosed funding
1unicorns
228have raised
$16.9 billion in disclosed funding across 328 tracked companies tells you everything about where serious capital is betting in biotech right now. This directory ranks the top Cell Therapy companies across the United States by disclosed equity funding and recent funding momentum, and the numbers justify the attention. The global market sat at $7.8B in 2019 and is forecast to reach $48.1B by 2027, a CAGR of 18.7% driven by chronic disease prevalence and accelerating advances in stem cell research. Regulatory hurdles remain a real friction point, but approvals are moving, and capital is moving faster.
The funding distribution here isn't flat. Lyell Immunopharma has pulled in $493M, Orca Bio sits at $300M, and Aspen Neuroscience has raised $224M, meaning a handful of players are capturing an outsized share of that $16.9B pool. I'd watch the mid-tier names too, because the gap between them and the leaders is closing. So what separates the companies worth tracking from the noise? Backing quality matters as much as round size: HHS, RA Capital Management, and Arch Venture Partners are the most active investors in this cohort, and their presence in a cap table is a signal worth reading carefully. Cell therapy manufacturing complexity remains the sector's real operational test.
Sources & further reading
- Cell Therapy Market Climbs on Positive Outlook of Booming Sales 2020-2
- Growing Approvals for Cell-based Therapies Fuels the Sector
Ranked: Best Cell Therapy companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ArsenalBio Developer of immune cell therapies for cancer treatment | $631M | 23 mo ago | 178 178 → 178 (+0%) · sector median +31% | 2019 | Ken Drazan Co-Founder & CEO | — | — | — |
| 2 | Allogene Therapeutics Developer of chimeric antigen receptor cell therapy to treat cancer | $532M | 25 mo ago | 303 303 → 215 (-29%) · sector median +31% | 2018 | David Chang President and Chief Executive Officer | 5 signals ▼29% Earnings · IPO · Funding | 414 patents Engineering allogeneic CAR‑T cells with immune‑evasion, switch receptors, and dosing technologies | 3 launchs |
| 3 | Lyell Immunopharma Developer of CAR- T therapy for cancer treatment 45Patents top 14%Innovation top 21%Funding top 24%Talent top 28% All 11 signals ▾Patentstop 14% Innovationtop 21% Fundingtop 24% Talenttop 28% Techtop 30% Moatbottom 46% Globalbottom 42% Marketbottom 32% Growthbottom 32% Newsbottom 23% Fin. healthbottom 18% Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $493M | 10 mo ago | 224 224 → 233 (+4%) · sector median +31% | 2018 | Stan Riddell Co-Founder | — | 163 patents Patents concentrated in chemistry & materials | — |
| 4 | Capstan Therapeutics Developer of cell therapies for a broad range of diseases | $340M | 27 mo ago | 75 | 2021 | Laura Shawver CEO | — | — | — |
| 5 | Obsidian Therapeutics Developer of engineered cell and gene therapies for multiple diseases | $325M | 26 mo ago | 80 80 → 105 (+31%) · sector median +31% | 2015 | Michael Gilman CEO | 3 signals ▲200% M&A · Leadership | 158 patents Engineered cytokine fusion proteins and regulated cell‑therapy platforms for cancer immunotherapy | — |
| 6 | Poseida Therapeutics Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | $324M | 34 mo ago | 259 | 2015 | — | — | 426 patents Patents concentrated in chemistry & materials | — |
| 7 | Kyverna Therapeutics Developer of T-cell therapy for autoimmune disease | $322M | 34 mo ago | 96 96 → 160 (+67%) · sector median +31% | 2018 | — | 4 signals ▼89% Earnings | — | — |
| 8 | Neurona Therapeutics Developer of cell-based therapies to treat intractable neurological diseases 55Funding top 22%Moat top 31%Growth top 32%AI top 45% All 8 signals ▾Fundingtop 22% Moattop 31% Growthtop 32% AItop 45% Talentbottom 49% Marketbottom 43% Globalbottom 39% Techbottom 30% Funding: Raised $316M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $316M | 14 mo ago | 67 67 → 116 (+73%) · sector median +31% | 2008 | Cory Nicholas CEO | — | — | 1 award |
| 9 | Orca Bio 🦄 Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders 74Funding top 18%Growth top 26%Moat top 26%Talent top 38% All 8 signals ▾Fundingtop 18% Growthtop 26% Moattop 26% Talenttop 38% Techtop 40% Markettop 42% Globalbottom 37% Newsbottom 18% Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $300M | 5 mo ago | 66 | 2016 | Jeroen Bekaert Co-Founder & COO | — | — | 1 expansion |
| 10 | Be Bio Developer of B cell therapies for multiple therapeutic areas 50Funding top 22%Moat top 31%Market top 48%Global bottom 36% All 4 signals ▾Fundingtop 22% Moattop 31% Markettop 48% Globalbottom 36% Funding: Raised $264M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $264M | 17 mo ago | 103 | 2020 | — | — | — | — |
| 11 | Abcuro Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer 42Funding top 22%Moat top 28%Growth top 35%Patents top 35% All 9 signals ▾Fundingtop 22% Moattop 28% Growthtop 35% Patentstop 35% Innovationtop 36% Globalbottom 42% Marketbottom 32% Techbottom 19% Newsbottom 17% Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $252M | 16 mo ago | 24 24 → 40 (+67%) · sector median +31% | 2015 | — | — | 48 patents Therapeutic anti‑KLRG1 antibodies for treating immune‑cell malignancies and autoimmune diseases | — |
| 12 | Tenaya Therapeutics Developer of regenerative and gene therapeutics for heart failure | $248M | 16 mo ago | 141 141 → 93 (-34%) · sector median +31% | 2016 | Benoit Bruneau Co-Founder | — | 207 patents Engineered AAV capsids and CRISPR guides for cardiac gene‑therapy targeting PLN mutations | — |
| 13 | Aspen Neuroscience Provider of genomic-based personalised pluripotent stem cell therapy 64Funding top 17%Patents top 23%Moat top 28%Innovation top 33% All 10 signals ▾Fundingtop 17% Patentstop 23% Moattop 28% Innovationtop 33% Growthtop 35% Newstop 45% Marketbottom 49% Talentbottom 49% Techbottom 46% Globalbottom 45% Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $224M | 6 mo ago | 94 | 2018 | Damien Mcdevitt President | — | 57 patents Patents concentrated in computing, sensing & instrumentation | — |
| 14 | Outpace Bio Developer of T-cell therapies for cancer treatment | $200M | 23 mo ago | 48 48 → 73 (+52%) · sector median +31% | 2020 | Scott Boyken Co-Founder | — | — | — |
| 15 | Garuda Developer of stem cell-based therapies to treat multiple diseases | $182M | 20 mo ago | 44 | 2021 | David Scadden Co-Founder | — | 2 patents Patents concentrated in computing, sensing & instrumentation | — |
| 16 | Marker Therapeutics Developer of T-cell based therapeutics for cancer treatment 42Talent top 15%Funding top 18%News top 47%Tech top 50% All 9 signals ▾Talenttop 15% Fundingtop 18% Newstop 47% Techtop 50% Moattop 50% Marketbottom 43% Growthbottom 40% Globalbottom 32% Fin. healthbottom 29% Talent: Analyst team rating 5/5 Funding: Raised $154M across 23 rounds · 23 rounds over 10 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $154M | 9 mo ago | 67 | 1991 | — | 3 signals Earnings | — | — |
| 17 | Wugen Developer of CAR-T cell therapy for treatingT-cell malignancies 64Talent top 15%Funding top 21%Patents top 26%Moat top 28% All 9 signals ▾Talenttop 15% Fundingtop 21% Patentstop 26% Moattop 28% Innovationtop 30% Techbottom 45% Marketbottom 43% Globalbottom 40% Newsbottom 22% Talent: Analyst team rating 5/5 Funding: Raised $136M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $136M | 9 mo ago | 81 | 2018 | — | — | 41 patents Immunotherapy platforms: memory NK cell expansion, CD3‑engineered immune cells, CARs, bispecific antibodies | 1 job opening |
| 18 | Cartesian Therapeutics Pioneering mRNA cell therapies for autoimmune diseases, expanding treatment possibilities 48Funding top 24%Moat top 37%Fin. health top 42%Growth top 44% All 8 signals ▾Fundingtop 24% Moattop 37% Fin. healthtop 42% Growthtop 44% Markettop 49% Newsbottom 38% Globalbottom 32% Techbottom 26% Funding: Raised $133M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Top 15% by revenue among 13 tracked Immunotherapy companies · Editorial + unicorn rating 2/10 rank vs industry peers · Fliar Intelligence Index 48/100 | $133M | 12 mo ago | 26 | 2016 | — | 3 signals ▼75% Announcements | — | 1 partnership |
| 19 | Ossium Health Developer of cell therapy products for blood cancers, tissue damage healing & radiation poisoning | $125M | 22 mo ago | 87 | 2016 | Kevin Caldwell Co-Founder & CEO | — | 81 patents Cryopreservation and processing of bone marrow, stromal, and lymphocyte cells for therapies | — |
| 20 | Cellino Developer of autologous cell therapies | $125M | 21 mo ago | 43 43 → 107 (+149%) · sector median +31% | 2017 | Matthias Wagner Co-Founder & CTO | — | — | 1 award |
| 21 | Abata Developer of cell therapies for autoimmune and inflammatory disease | $110M | 22 mo ago | 50 | 2021 | Samantha Singer President & Chief Executive Officer | — | — | — |
| 22 | Stylus Medicine Developer of gene-based therapeutics for multiple diseases | $85M | 13 mo ago | 21 | 2022 | — | — | — | — |
| 23 | GCTx Developer of a synthetic biology platform for cell programming | $75M | 20 mo ago | 15 | 2019 | Cory Smith Scientific Co-Founder and Head of Discovery Platforms | — | — | 2 job openings · 1 award |
| 24 | Nuo Therapeutics Developer of regenerative products for wound care 53Growth top 11%Funding top 24%Talent top 45%Fin. health top 50% All 9 signals ▾Growthtop 11% Fundingtop 24% Talenttop 45% Fin. healthtop 50% Moatbottom 38% Globalbottom 37% Marketbottom 33% Techbottom 30% Newsbottom 21% Growth: Revenue +143% YoY · Fresh capital in last 24 mo Funding: Raised $64.6M across 18 rounds · 18 rounds over 16 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $65M | 10 mo ago | 10 10 → 19 (+90%) · sector median +31% | 2001 | David Jorden CEO & Director | — | — | — |
| 25 | Link Cell Therapies Developer of CAR-T cell therapies for the treatment of cancer 11Funding top 29%Tech bottom 41%Global bottom 29%Market bottom 19% All 4 signals ▾Fundingtop 29% Techbottom 41% Globalbottom 29% Marketbottom 19% Funding: Raised $60.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) Tech: 19 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 6 mo ago | 8 | 2022 | — | — | — | — |
| 26 | Shinobi Therapeutics Developer of immune-evasive iPSC-derived cell treatments for various diseases | $60M | 22 mo ago | — | 2023 | Shin Kaneko Co-Founder | — | — | — |
| 27 | Verismo Therapeutics Developer of CAR-T cell therapies for cancer 16Funding top 32%Moat top 39%Tech bottom 43%Global bottom 38% All 6 signals ▾Fundingtop 32% Moattop 39% Techbottom 43% Globalbottom 38% Marketbottom 25% Newsbottom 21% Funding: Raised $50.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 16/100 | $50M | 1 mo ago | 9 | 2020 | — | — | — | 1 job opening · 1 partnership · 1 award |
| 28 | Epibone Developer of patient‑specific bone and cartilage grafts 50Moat top 25%Talent top 28%Funding top 29%Patents top 32% All 9 signals ▾Moattop 25% Talenttop 28% Fundingtop 29% Patentstop 32% Innovationtop 38% Techtop 46% Globalbottom 42% Marketbottom 31% Newsbottom 21% Moat: Editorial + unicorn rating 7/10 · IP moat: 48 patents Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 9 mo ago | 34 | 2013 | Elisa Cimetta Co-Founder | — | 48 patents Regenerative orthopedic biomaterials for injectable cartilage/tendon/ligament repair and surgical tools. | — |
| 29 | PeproMene Bio Developer of T-cell therapeutics for cancer treatment | $44M | 17 mo ago | 6 | 2016 | — | — | — | — |
| 30 | Kernal Biologics Developer of mRNA therapeutics for immuno-oncology using deep learning technology | $35M | 8 mo ago | 18 18 → 22 (+22%) · sector median +31% | 2016 | Burak Yilmaz Co-Founder | — | 27 patents Targeted lipid-based delivery systems for oncoselective cancer therapeutics | — |
| 31 | March Biosciences Developer of CAR-T cell therapies for malignancies | $33M | 20 mo ago | — | 2022 | Max Mamonkin Co-Founder and CSO | 3 signals ▲200% Leadership | — | — |
| 32 | Immunis Developer of cell therapies for age-related and disease-related immune deficits 32Patents top 24%Innovation top 28%Moat top 32%Funding top 39% All 6 signals ▾Patentstop 24% Innovationtop 28% Moattop 32% Fundingtop 39% Globalbottom 40% Marketbottom 21% Patents: 48 patents matched (strict assignee match) · 45 filings since 2022 vs 3 in 2017-21 Innovation: 48 patents (top 32% of patent-holders) · 45 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $30M | 17 mo ago | 3 | 2018 | — | — | 48 patents Prostate cancer liquid biopsy diagnostics using secretome-derived biomarkers | 1 launch |
| 33 | Incyclix Bio A next-generation cell cycle control company advancing precision treatments for cancer 21Funding top 25%Talent top 28%Moat top 39%Tech bottom 31% All 6 signals ▾Fundingtop 25% Talenttop 28% Moattop 39% Techbottom 31% Globalbottom 29% Marketbottom 20% Funding: Raised $30.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $30M | 2 mo ago | 6 | 2020 | Patrick Roberts Co-Founder & CEO | — | — | — |
| 34 | Organogenesis Regenerative tissue innovations for advanced wound care and surgical solutions | $30M | 19 mo ago | 856 856 → 921 (+8%) · sector median +31% | 1985 | Gary Gillheeney CEO | 7 signals ▼73% Earnings | 209 patents Collagen-based biomaterials for wound healing, tissue regeneration, and anti‑inflammatory assay kits. | — |
| 35 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +31% | 2015 | — | 16 signals ▲45% Board · Leadership · Earnings | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 36 | Oisín Biotechnologies Developer of genetically targeted intervention therapy for age-related diseases | $25M | 18 mo ago | 18 | 2014 | Gary Hudson Co-Founder & Chairman | — | — | — |
| 37 | Secretome Therapeutics Developer of cell-based therapies for multiple diseases | $22M | 0 mo ago | 8 | 2018 | Sudhish Sharma Co-Founder | — | — | — |
| 38 | Coya Therapeutics Developer of therapeutics for cell therapy and exosome therapy | $20M | 19 mo ago | 6 | 2020 | — | 8 signals Funding · Leadership · IPO | — | — |
| 39 | BioRestorative Therapies Developer of stem cell therapies to address multiple diseases 27News top 24%Moat top 32%Funding top 33%Patents top 42% All 11 signals ▾Newstop 24% Moattop 32% Fundingtop 33% Patentstop 42% Growthtop 43% Techtop 45% Innovationbottom 48% Globalbottom 41% Talentbottom 40% Fin. healthbottom 26% Marketbottom 21% News: 9 BI events in 12 mo (of 27 tracked, 6 types) · +80% YoY Moat: Editorial + unicorn rating 4/10 · IP moat: 45 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $20M | 8 mo ago | 10 10 → 21 (+110%) · sector median +31% | 1997 | Lance Alstodt Chairman and CEO | 9 signals ▲80% Funding · Earnings · Leadership | 45 patents Patents concentrated in chemistry & materials | — |
| 40 | Coeptis Therapeutics Developer of cell therapies for the treatment of cancer | $18M | 10 mo ago | 5 | 2016 | Dave Mehalick Co-Founder | — | — | — |
| 41 | Trailhead Biosystems Developer of cell therapies for the treatment of multiple diseases | $17M | 5 mo ago | 13 | 2015 | Jan Jensen Co-Founder & CEO | — | 96 patents Stem cell differentiation protocols for therapeutic blood, neural, and pancreatic cells | 1 launch |
| 42 | Cellinfinity Bio Developer of cell therapies for cancer treatment | $13M | 17 mo ago | 9 | 2021 | Sidi Chen Founder | — | — | — |
| 43 | ImmuneBridge Developer of allogeneic cellular medicines to treat cancer | $12M | 14 mo ago | 4 | 2018 | Jesse Cotari Co-Founder | — | 10 patents Patents concentrated in health & consumer products | — |
| 44 | Cellvie Developer of cell-derived therapeutics solutions for the treatment of cardiac health, stroke & kidney… | $10M | 9 mo ago | 12 | 2020 | Alexander Schueller Founder & CEO | — | 10 patents Optimizing adoptive cell therapy by generating enhanced immune cell populations for immunotherapy | — |
| 45 | Hexem bio Developer of stem cell-based therapies for aging and disease prevention 29Talent top 28%Funding top 41%Global top 45%Tech bottom 43% All 5 signals ▾Talenttop 28% Fundingtop 41% Globaltop 45% Techbottom 43% Marketbottom 25% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $10.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $10M | 2 mo ago | — | 2024 | Mo Ebrahimkhani Co-Founder | — | — | — |
| 46 | Aegle Therapeutics Developing extracellular vesicle therapies for debilitating rare diseases and dermatological disorders | $6M | 5 mo ago | 4 | 2013 | — | — | — | — |
| 47 | Angiocrine Bioscience Therapeutics based on genetically modified endothelial cells | $4M | 9 mo ago | 29 | 2012 | — | — | 117 patents Patents concentrated in health & consumer products | — |
| 48 | BioXyTran Developing platform technologies in Glycovirology, Hypoxia, and Degenerative Diseases | $2M | 3 mo ago | 3 | 2008 | — | — | 2 patents Patents concentrated in health & consumer products | — |
| 49 | HemoGenyx Developer of cell and gene therapies to treat blood diseases and viral infections | $1M | 4 mo ago | 14 | 2014 | — | — | 6 patents Bispecific antibody-mediated depletion of hematopoietic stem/progenitor cells for conditioning transplants | — |
| 50 | BSD Developer of multigenic therapies for complex diseases | $705K | 3 mo ago | 7 | 2020 | Thomas Reed Founder & CEO | — | — | — |
Top 12 Cell Therapy companies in United States
#1
Orca Bio 🦄Series F · Menlo Park, California · founded 2016 · 66 employees$300Mraised▾
Orca Bio 🦄
Series F · Menlo Park, California · founded 2016 · 66 employees
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patient's new immune system.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 18%Growth
top 26%Moat
top 26%Talent
top 38%Tech
top 40%Market
top 42%Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) · Last round Series F (Jan 2026)
Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 9/10 · Unicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 5.3% of this cohort's audience · 158 engagements/post (5.1× cohort median)
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Jan 2026Series F$250M
- Nov 2019Series D$192M
Founders & team
Investors
Lightspeed Venture Partners, 8VC, DCVC, ND Capital, IMRF, Kaiser Permanente
Tech stack
Amazon Web ServicesApple Icloud MailBackbone.JsBrizy WordpressBunnyBunny Fonts
#2
Series A · Philadelphia, Pennsylvania · founded 2020 · 9 employees$50Mraised▾
Series A · Philadelphia, Pennsylvania · founded 2020 · 9 employees
Developer of CAR-T cell therapies for cancer. The KIR-CAR cell therapy provides stimulation to the cell that enhances the T-cell activation and elimination of antigen-negative tumor cells. It provides a product SynKIR-meso for pancreatic cancer, ovarian cancer, and mesothelioma.
Fliar Intelligence Index™ 16how this company ranks against its industry peers
Funding
top 32%Moat
top 39%Tech
bottom 43%Global
bottom 38%Market
bottom 25%News
bottom 21%Funding: Raised $50.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Tech: 21 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Hsts, Http/3
Audience (LinkedIn): 7k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Process & Analytical Development Specialist
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Cryoport) announced in 12 mo
Funding rounds
- Apr 2026Series A$28M
- Jul 2023Seed$19.2M
- Feb 2023Seed$7M
- Apr 2021Seed$16M
Investors
DongKoo Bio& Pharma, BRV Capital Management, Ignite Innovation
#3
Series C · San Diego, California · founded 2018 · 94 employees$224Mraised▾
Series C · San Diego, California · founded 2018 · 94 employees
Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 17%Patents
top 23%Moat
top 28%Innovation
top 33%Growth
top 35%News
top 45%Funding: Raised $224M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Series C (Nov 2025)
Patents: 57 patents matched (strict assignee match) · 51 filings since 2022 vs 6 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 57 patents · Soonicorn
Audience (LinkedIn): 13k LinkedIn followers — 2.8% of this cohort's audience
Funding rounds
- Nov 2025Series C$115M
- Dec 2022Conventional Debt$40M
- May 2022Series B$147.5M
- Apr 2020Series A$70M
Founders & team
Investors
Orbimed, Arch Venture Partners, Frazier Healthcare Partners, Domain Associates, S32, Google Ventures
Tech stack
CloudflareCloudflare Bot ManagementCore-JsGeneratepressGeneratepress Gp PremiumGodaddy
#4
Series A · Dallas, Texas · founded 2018 · 8 employees$22.1Mraised▾
Series A · Dallas, Texas · founded 2018 · 8 employees
Developer of cell-based therapies for multiple diseases. It offers a lead product STM-21 to prevent the inflammatory toxicities of cancer treatment which include cisplatin-induced acute kidney injury. It also offers STM-01 a cellular therapy comprised of the neonatal MSCs for restoring cardiac function in a heart attack.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Mar 2026Series B$250K
- Nov 2024Series B$20.4M
- Oct 2019Seed$1.5M
Founders & team
Investors
Maryland Momentum Fund, Parent Project Muscular Dystrophy, RA Capital Management, USM
Tech stack
CloudflareCloudflare Bot ManagementDiviGodaddyGodaddy CoblocksGoogle Analytics
#5
Public · Cambridge, Massachusetts · founded 2015 · 51 employees$26.4Mraised▾
Public · Cambridge, Massachusetts · founded 2015 · 51 employees
Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Innovation
top 16%Patents
top 16%News
top 28%Moat
top 29%Growth
top 31%Partners
top 32%Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21
Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 · Latest publication 2026
News: 16 BI events in 12 mo (of 40 tracked, 7 types) · +45% YoY · Top themes: Board, Leadership, Earnings
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- May 2026Post IPO$30M
- Nov 2022Post IPO$30M
- Dec 2016Series A$16.4M
- Jun 2015Seed$10M
Investors
MDB Capital
Tech stack
Google AnalyticsGoogle Font ApiJqueryJquery MigrateModernizrMysql
#6
Public · San Francisco, California · founded 2018 · 224 employees$493Mraised▾
Public · San Francisco, California · founded 2018 · 224 employees
Developer of CAR- T therapy for cancer treatment. The lead CAR program LYL797is developed for the treatment of ROR1+ non-small cell lung cancer and triple-negative breast cancer. Another candidate LYL845 is an autologous TIL therapy for the treatment of multiple solid tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Patents
top 14%Innovation
top 21%Funding
top 24%Talent
top 28%Tech
top 30%Moat
bottom 46%Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 · Latest publication 2026
Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21
Funding: Raised $493M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) · Last round Post IPO (Jul 2025)
Audience (LinkedIn): 22k LinkedIn followers — 4.7% of this cohort's audience
Funding rounds
- Jul 2025Post IPO$100M
- Mar 2020Series C$493M
- 2018Seed—
Founders & team
Investors
GSK, Sahsen Ventures, 8VC, Foresite Capital, Arch Venture Partners, Mubadala
Tech stack
Amazon Web ServicesBootstrapCloudflareCloudflare Bot ManagementFont AwesomeGoogle Analytics
#7
Series B · Durham, North Carolina · founded 2020 · 6 employees$30Mraised▾
Series B · Durham, North Carolina · founded 2020 · 6 employees
A next-generation cell cycle control company advancing precision treatments for cancer. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor entering clinical development and has therapeutic targets across many tumor types, including ovarian, breast, and lung cancers.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 25%Talent
top 28%Moat
top 39%Tech
bottom 31%Global
bottom 29%Market
bottom 20%Funding: Raised $30.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series B (Apr 2026)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Apr 2026Series B$5M
- Aug 2025Series B$11.2M
- Mar 2022Series B$30M
Founders & team
Investors
Boxer Capital, RA Capital Management, Eshelman Ventures, Lilly, Pharmacosmos, Cape Fear BioCapital
#8
Public · Houston, Texas · founded 1991 · 67 employees$153.9Mraised▾
Public · Houston, Texas · founded 1991 · 67 employees
Developer of T-cell based therapeutics for cancer treatment. The company's lead product candidates are used against triple-negative breast cancer and ovarian cancer. The company is also developing peptide vaccines for the treatment purpose.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Talent
top 15%Funding
top 18%News
top 47%Tech
top 50%Moat
top 50%Market
bottom 43%Talent: Analyst team rating 5/5
Funding: Raised $154M across 23 rounds · 23 rounds over 10 yrs (2.3/yr) · Last round Grant (prize money) (Aug 2025)
News: 3 BI events in 12 mo (of 22 tracked, 6 types) · +0% YoY · Top themes: Earnings
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- Aug 2025Grant (prize money)$1.3M
- Jun 2025Grant (prize money)$1.2M
- May 2025Grant (prize money)$2M
- Apr 2025Grant (prize money)$2M
Investors
New Enterprise Associates, Aisling Capital, state.tx.us, FDA, NIH, Blue Owl
Tech stack
Apache Http ServerApple Icloud MailBootstrapCookieyesGodaddyGoogle Analytics
#9
Series A · San Carlos, California · founded 2022 · 8 employees$60Mraised▾
Series A · San Carlos, California · founded 2022 · 8 employees
Developer of CAR-T cell therapies for the treatment of cancer
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 29%Tech
bottom 41%Global
bottom 29%Market
bottom 19%Funding: Raised $60.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) · Last round Series A (Dec 2025)
Tech: 19 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Http/3
Global: Single-market focus (United States)
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. Jonathan & Johnson) announced in 12 mo
Funding rounds
- Dec 2025Series A$60M
- 2022Seed—
Investors
Johnson & Johnson Innovation, Samsara BioCapital, Wing Venture Capital, Sheatree Capital
#10
Series C · St. Louis, Missouri · founded 2018 · 81 employees$135.7Mraised▾
Series C · St. Louis, Missouri · founded 2018 · 81 employees
Developer of CAR-T cell therapy for treating T-cell malignancies. The company has developed an allogeneic CAR-T therapy platform for the treatment. Deletion of the T-cell receptor (TCR) enables the use of T-cells from healthy donors without the risk of life-threatening Graft vs. Host Disease (GvHD). It has developed a pipeline for Head & Neck Cancer, Melanoma, and Solid Tumors.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Talent
top 15%Funding
top 21%Patents
top 26%Moat
top 28%Innovation
top 30%Tech
bottom 45%Talent: Analyst team rating 5/5
Funding: Raised $136M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series C (Aug 2025)
Patents: 41 patents matched (strict assignee match) · 38 filings since 2022 vs 3 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · hiring: Data Science and Biometrics, Data Management
Activity (LinkedIn): 1 partnerships (incl. Wugen) announced in 12 mo
Funding rounds
- Aug 2025Series C$115M
- Jul 2021Series B$98.5M
- Apr 2020Series A$37.2M
- 2019Seed—
Investors
BioGenerator, Abingworth, Tybourne Capital Management, Fidelity Investments, ICG, LYZZ Capital
Tech stack
Amazon Web ServicesAnimate.CssBootstrapCore-JsElementorFont Awesome
#11
Acquired · San Francisco, California · founded 2008 · 67 employees$315.7Mraised▾
Acquired · San Francisco, California · founded 2008 · 67 employees
Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Growth
top 32%AI
top 45%Talent
bottom 49%Market
bottom 43%Funding: Raised $316M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) · Last round Series E (Mar 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Growth: Headcount 55 → 67 (+22%) across vintages · Fresh capital in last 24 mo
Audience (LinkedIn): 12k LinkedIn followers — 2.5% of this cohort's audience · 138 engagements/post (4.4× cohort median)
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Clinical Specialist
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Mar 2025Series E$102M
- Feb 2024Series E$120M
- Dec 2022Series D$72M
- Jun 2021Series C$41.5M
Founders & team
Investors
UCB Ventures, Ironfire Ventures, Alexandria, Sphera Fund, The Column Group, Viking Global Investors
Tech stack
Apache Http ServerApple Icloud MailCookieyesGoogle AnalyticsGoogle Hosted LibrariesHsts
#12
Series B · Beachwood, Ohio · founded 2015 · 13 employees$16.7Mraised▾
Series B · Beachwood, Ohio · founded 2015 · 13 employees
Developer of cell therapies for the treatment of multiple diseases. The company uses HD-DoE technology platform to develop a pipeline for diabetes, cancer, bone marrow, Huntington's disease, and more.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers
Activity: 1 product launches announced in 12 mo
Funding rounds
- Jan 2026Series B$20M
- May 2025Series B$20M
- Oct 2022Series A$10M
- Nov 2020Series A$6.6M
Founders & team
Investors
Innovation Fund America, MAK Capital, BioEnterprise
Tech stack
Animate.CssAnime.JsCart FunctionalityCloudflareCloudflare Bot ManagementComplianz
Funding & investor landscape
$16.9Btotal disclosed funding
225companies funded
930disclosed rounds
5rounds last 90 days
Most active investors
Notable founders
Jeroen Bekaert
Co-Founder & COO · Orca Bio
Ivan Dimov
Co-Founder & Co-CEO · Orca Bio
Damien Mcdevitt
President · Aspen Neuroscience
Sudhish Sharma
Co-Founder · Secretome Therapeutics
Muthukumar Gunasekaran
Co-Founder · Secretome Therapeutics
Stan Riddell
Co-Founder · Lyell Immunopharma
Crystal Mackall
Co-Founder · Lyell Immunopharma
Patrick Roberts
Co-Founder & CEO · Incyclix Bio
Jay Strum
Co-Founder · Incyclix Bio
Cory Nicholas
CEO · Neurona Therapeutics
Jan Jensen
Co-Founder & CEO · Trailhead Biosystems
Mo Ebrahimkhani
Co-Founder · Hexem bio
Prism market signals · United States · country-scoped Prism corpus, 11,800,581 docs
Market landscape — 10 sub-themes by coverage
Share of Cell Therapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Cell Therapy is moving in the United States
A read on the academic research around Cell Therapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 5,189 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 84% → 82% across 2008–2026.
top research entities
- Harvard University203
- The University of Texas MD Anderson Cancer Center174
- University of Pennsylvania153
- Stanford University141
- Memorial Sloan Kettering Cancer Center127
leading researchers
Cesar V. Borlongan · Joshua M. Hare · Renier J. Brentjens · Anthony Atala · Yan-Ruide Li · Maria Siemionow · Reona Sakemura · Heng Mei
▲
Breakthroughs1,183 · 23%
▲ 17%→26% share
▲1.5× share momentum1 median citations59% since 2021mostly methods-led
CAR-T breakthrough research is surging — chimeric antigen receptor papers rose 5× (48→240), with cytotoxicity and refractory disease newly emerging.
rising sub-themes (early→recent)
- Chimeric antigen receptor48→240
- Immunotherapy28→169
- T cell29→135
- Immune system33→130
- Cancer research42→107
Newly emergingRefractory (planetary science) 0→13 · Cytotoxicity 0→12 · Myeloid leukemia 0→11
Landmark Mesenchymal Stem Cells as Therapeutics · 765 cites
◆
Advancements2,365 · 46%
▼ 50%→44% share
▼0.9× share momentum5 median citations48% since 2021mostly empirical
CAR-T advancement papers quadrupled (77→341) while epigenetics and extracellular vesicles newly entered U.S. cell therapy research.
rising sub-themes (early→recent)
- Chimeric antigen receptor77→341
- Immunotherapy89→238
- Immune system78→216
- T cell59→178
- Cancer research70→142
Newly emergingLung cancer 0→9 · Extracellular vesicle 0→8 · Epigenetics 0→8
Landmark CAR-T cell therapy: current limitations and potential strategies · 2,614 cites
▼
Concerns1,243 · 24%
▼ 27%→22% share
▼0.8× share momentum12 median citations47% since 2021mostly reviews
Tumor microenvironment concerns intensified 9× (5→44); radiation therapy and targeted therapy risks are newly flagged in U.S. cell therapy research.
rising sub-themes (early→recent)
- Chimeric antigen receptor42→218
- Immunotherapy40→159
- Immune system33→98
- T cell21→68
- Tumor microenvironment5→44
Newly emergingMyeloid leukemia 0→11 · Radiation therapy 0→10 · Targeted therapy 0→9
Landmark Concise Review: MSC-Derived Exosomes for Cell-Free Therapy · 1,786 cites
RESEARCH HOTSPOTS · United States
Where cell therapy is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston295 · +0.42
SF Bay Area244 · +0.39
Philadelphia229 · +0.37
New York205 · +0.41
Los Angeles138 · +0.35
Seattle121 · +0.46
San Diego118 · +0.43
Atlanta118 · +0.39
Pittsburgh99 · +0.39
Chicago93 · +0.38
PATENT SIGNAL · United States
Who's filing cell therapy patents in the United States
United States cell therapy patent filing is accelerating — 2,819 filings from 817 assignees (2016–2025), led by JUNO Therapeutics, KITE Pharma, Janssen Biotech; annual filings 86→414.
2,819 filings817 assigneespeak 414/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- JUNO Therapeutics338
- KITE Pharma251
- Janssen Biotech110
- Hutchinson FRED Cancer RES102
- US Health101
- Memorial Sloan Kettering Cancer 99
- Purdue Research Foundation73
- Seattle Childrens Hospital DBA S72
Common questions
How many Cell Therapy companies are there in United States?
Radar tracks 328 indexable Cell Therapy companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Cell Therapy companies in United States?
The Cell Therapy companies in United States on this list have raised a combined $16.9B in disclosed equity funding across 225 funded companies.
Which is the highest-funded Cell Therapy company in United States?
Sana Biotechnology is the highest-funded Cell Therapy company in United States, with $821M in disclosed equity funding.
How many Cell Therapy companies in United States are funded?
225 of the 328 Cell Therapy companies in United States on this list have disclosed at least one equity funding round.
How many Cell Therapy unicorns are there in United States?
1 Cell Therapy company in United States on this list is valued at $1B or more.
Who are the top investors in United States Cell Therapy companies?
The most active investors in United States Cell Therapy companies on this list include HHS, RA Capital Management, Alexandria, Arch Venture Partners, Citadel.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.